Ireland
--:--IST
Recruiting Phase 1

Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults

NCT07688369 · tracked via the Priya Life Science Australia tracker
Sponsor
Serum Institute of India Pvt. Ltd
Phase
Phase 1
Started
2026-09-11
Last updated
2026-09-29

Condition(s) studied

Polio Immunity

Investigational drug(s) / intervention(s)

Recombinant Poliomyelitis Vaccine (rPV)Inactivated Poliomyelitis Vaccine (IPOL)

Recombinant Poliomyelitis Vaccine (rPV): Recombinant Poliomyelitis Vaccine (VLP) is manufactured by Serum Institute of India Pvt. Ltd.

Inactivated Poliomyelitis Vaccine (IPOL): IPOL (inactivated poliovirus vaccine) is a marketed Sanofi

Study summary

The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Key Inclusion Criteria: * Healthy Volunteers aged between 18 to 60 years inclusive. * Good physical and mental health based on medical history, physical examination, clinical laboratory,electrocardiogram (ECG), and vital signs, as judged by the Investigator. * Participants must refrain from strenuous exercise within 96 hours (4 days) prior to Screening, Day 1, Day 8,and Day 30.. * Willing and able to comply with restrictions of nicotine (i.e., tobacco and nicotine products) usethroughout the study is not permitted from within 48 hours (2 days) prior to Screening, from Day 1 until Day8, and within 48 hours (2 days) prior to the end of study visit. * Participants must agree to use highly effective contraception from Day 1 until 90 days after the last studyvisit. Key Exclusion Criteria: * History of Polio * Any vaccination received 30 days before Screening and Day 30 * Pregnant or lactating females * BMI \>35.0kg/m2 * History of alcohol abuse or drug addiction * Have received any polio vaccines within 6 months prior to screening. * History of major surgeries * History of receipt of a blood transfusion, other blood products, or immunoglobulins in 3 months prior tostudy vaccination * any confirmed or suspected congenital or acquired immunosuppressive or immunodeficient condition.

Primary outcome measure(s)

  • The incidence, severity and relationship of solicited adverse events (AEs) during 7-day and unsolicited AEs during 30-day follow-up period after rPV and IPOL vaccination — 30 days

Trial sites (1)

FacilityCityRegionStatus
Doherty Clinical Trials Limited East Melbourne Victoria Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07688369 on ClinicalTrials.gov ↗ ← All trials in Australia